SUBSCRIBE
SUBSCRIBE

Joshua R. Mansbach

Opinion author

Joshua R. Mansbach is a healthcare communications strategist who has led corporate and brand strategy for global Fortune 500 pharmaceutical, biotech and life science companies at all stages of the lifecycle, from stealth to commercialization. He has led communications as part of global agencies on behalf of companies including Pfizer, AstraZeneca, and Novartis, and he specializes in helping companies create the story of how companies are solving the industry’s most urgent clinical, patient care, commercial, and market access challenges.

Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
Opinion
Rare Disease Patients Can’t Wait for Regulatory Process
The U.S. Senate has a plan to improve drug development for rare disease patients. The exit of controversial CBER chief Vinay Prasad will help clear the path.
March 11, 2026
 · 
5 min read
 · 
Joshua R. Mansbach
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
Opinion
Balancing Safety Access in Rare Disease—Lessons From Sarepta
Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example of why.
February 25, 2026
 · 
6 min read
 · 
Joshua R. Mansbach
Time is money concept. Vector logo of a clock flowing into dollar symbol
Drug Pricing
Opinion: Pricing Transparency Is Coming to the Pharma Industry
Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.
February 2, 2026
 · 
5 min read
 · 
Joshua R. Mansbach